Exelixis’ and Daiichi Sankyo’s Novel Antihypertensive Drug Minnebro® Hits the Japanese Market

Minnebro® Hits the Japanese Market
Exelixis and Daiichi Sankyo launched their novel anitihypertension product Minnebro® in Japan
Exelixis (EXEL) and Daiichi Sankyo (DSNKY) Limited informed that Daiichi has launched their novel antihypertension product Minnebro® (esaxerenone) tablets in Japan. Exelixis is expected to receive a $20 million milestone payment following Daiichi Sankyo’s first sale in Japan, as dictated under the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.